FDA Issues Draft Guidance on Container Closure Systems for Human Drugs and Biological Products

The U.S. Food and Drug Administration (FDA) has issued a new draft guidance for industry, “Container Closure Systems for Human Drugs and Biological Products,” providing updated recommendations for evaluating the quality of container closure systems (CCSs) used to package human drugs and biological products.

The draft guidance addresses pharmaceutical quality considerations, including chemistry, manufacturing, and controls (CMC), and reflects advances in container closure technologies and pharmaceutical product development.

What the Draft Guidance Covers

The draft guidance provides general principles and specific considerations for the development and assessment of container closure systems used for drug products and drug substances.

The guidance applies to applications for human drugs and biological products, including amendments and supplements to approved applications.

It also applies to:

• Container closure systems that are device constituent parts of combination products
• Container closure systems used to package the drug or biological product constituent parts of combination products
• Certain drug products marketed without an approved application under section 505G of the Federal Food, Drug, and Cosmetic Act

FDA states that a container closure system must provide adequate protection during storage and use without adversely affecting the safety, identity, strength, quality, or purity of the drug.

Addressing Advances in Container Closure Technologies

FDA notes that advances in pharmaceutical therapies and container closure technologies have led to changes in how these systems are designed, constructed, and evaluated.

Some newer container closure systems may perform functions beyond simply containing and protecting a product. For example, a system may also play a role in preparing the final dosage or delivering the product.

FDA’s draft guidance addresses the need to evaluate these additional functions and ensure they do not adversely affect product quality.

The agency also plans to issue additional topic-specific guidance addressing areas such as the evaluation of novel container closure systems and specific quality attributes and testing.

Replacing Previous FDA Guidance

When finalized, the new guidance will replace two existing FDA guidance documents:

• Container Closure Systems for Packaging Human Drugs and Biologics, issued in May 1999
• Container Closure Systems for Packaging Human Drugs and Biologics – Questions and Answers, issued in May 2002
• The updated guidance is intended to reflect advances in science, technology, and the development and evaluation of modern container closure systems.

What Companies Should Consider

Drug and biological product manufacturers should review the draft guidance and consider how FDA’s updated recommendations may affect existing and future product development and CMC strategies.

Organizations may want to evaluate:

• Current container closure system development and qualification practices
• Materials used in container closure components
• Product protection throughout storage and use
• Potential interactions between the container closure system and drug product
• Container closure considerations for combination products
• CMC documentation included in regulatory submissions
• Whether the proposed recommendations warrant comments to FDA

Because the guidance remains in draft form, stakeholders have an opportunity to provide FDA with feedback before the agency develops the final guidance.

Opportunity to Comment

FDA is accepting comments on the draft guidance through October 13, 2026.

Comments submitted by the deadline will be considered by FDA before the agency begins work on the final version of the guidance.

Docket: FDA-2026-D-7957

EAS Perspective

Container closure systems are an important component of pharmaceutical quality and can affect a product throughout its lifecycle. FDA’s new draft guidance reflects the evolution of both pharmaceutical products and the technologies used to contain, protect, prepare, and, in some cases, deliver them.

Drug and biological product manufacturers should review the draft guidance against their existing CMC and container closure strategies, particularly when developing new products, introducing new packaging technologies, or managing changes to existing systems.

Organizations that identify areas of concern or where additional clarification may be beneficial should also consider participating in FDA’s public comment process.